急性缺血性卒中患者血管内治疗后应用替罗非班的安全性及预后分析
目的：探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法：回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患者术后24h内是否使用替罗非班治疗分为替罗非班组（30例）和对照组（85例）。参照欧洲协作性急性卒中研究（ECASS）11标准评估24h内的出血转化，治疗后3个月时改良Rankin量表（mRS）超过2分定义为预后不优。采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后。结果：二元logistic回归分析提示，替罗非班治疗不增加...
Saved in:
| Published in | 浙江大学学报（医学版） Vol. 46; no. 4; pp. 397 - 404 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
温岭市第一人民医院神经内科,浙江温岭317500%浙江大学医学院附属第二医院神经内科,浙江杭州,310009
2017
浙江大学医学院附属第二医院神经内科,浙江杭州310009 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1008-9292 |
| DOI | 10.3785/j.issn.1008-9292.2017.08.09 |
Cover
| Abstract | 目的：探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法：回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患者术后24h内是否使用替罗非班治疗分为替罗非班组（30例）和对照组（85例）。参照欧洲协作性急性卒中研究（ECASS）11标准评估24h内的出血转化，治疗后3个月时改良Rankin量表（mRS）超过2分定义为预后不优。采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后。结果：二元logistic回归分析提示，替罗非班治疗不增加出血转化的风险（OR=0．437，95％CI：0.168-1．132，P〉0．05）；患者基线美国国立卫生研究院卒中量表（NIHSS）评分（OR=1．136，95％CI：1．014-1．273，P〈0．05）、血管再通（OR=0．060，95％CI：0．010-0．365，P〈0．01）、高血压（OR=4．233，95％CI：1．320-13．570，P〈0．05）和起病至治疗时间（OR=1．006。95％CI：1．001-1．01l，P〈0．05）与临床预后不优独立相关，而替罗非班治疗与临床预后不优无独立相关性（OR=1．923，95％CI：0．536-6．568，P〉0．05）。结论：急性缺血性卒中患者血管内治疗后使用替罗非班不会增加出血转化的风险。 |
|---|---|
| AbstractList | 目的：探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法：回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患者术后24h内是否使用替罗非班治疗分为替罗非班组（30例）和对照组（85例）。参照欧洲协作性急性卒中研究（ECASS）11标准评估24h内的出血转化，治疗后3个月时改良Rankin量表（mRS）超过2分定义为预后不优。采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后。结果：二元logistic回归分析提示，替罗非班治疗不增加出血转化的风险（OR=0．437，95％CI：0.168-1．132，P〉0．05）；患者基线美国国立卫生研究院卒中量表（NIHSS）评分（OR=1．136，95％CI：1．014-1．273，P〈0．05）、血管再通（OR=0．060，95％CI：0．010-0．365，P〈0．01）、高血压（OR=4．233，95％CI：1．320-13．570，P〈0．05）和起病至治疗时间（OR=1．006。95％CI：1．001-1．01l，P〈0．05）与临床预后不优独立相关，而替罗非班治疗与临床预后不优无独立相关性（OR=1．923，95％CI：0．536-6．568，P〉0．05）。结论：急性缺血性卒中患者血管内治疗后使用替罗非班不会增加出血转化的风险。 R743.3; 目的:探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析.方法:回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料.根据患者术后24 h内是否使用替罗非班治疗分为替罗非班组(30例)和对照组(85例).参照欧洲协作性急性卒中研究(ECASS)Ⅱ标准评估24 h内的出血转化,治疗后3个月时改良Rankin量表(mRS)超过2分定义为预后不优.采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后.结果:二元logistic回归分析提示,替罗非班治疗不增加出血转化的风险(OR=0.437,95%CI:0.168~1.132,P>0.05);患者基线美国国立卫生研究院卒中量表(NIHSS)评分(OR =1.136,95%CI:1.014 ~1.273,P <0.05)、血管再通(OR=0.060,95%CI:0.010 ~0.365,P <0.01)、高血压(OR=4.233,95%CI:1.320~13.570,P<0.05)和起病至治疗时间(OR=1.006,95%CI:1.001~1.011,P<0.05)与临床预后不优独立相关,而替罗非班治疗与临床预后不优无独立相关性(OR=1.923,95%CI:0.536~6.568,P>0.05).结论:急性缺血性卒中患者血管内治疗后使用替罗非班不会增加出血转化的风险. |
| Abstract_FL | Objective: To investigate the effect of tirofiban on hemorrhagic transformation and neurological outcome in patients with acute cerebral infarct treated with endovascular therapy.Methods: One hundred and fifteen patients with acute cerebral infarct who received endovascular stent mechanical thrombectomy in the Second Affiliated Hospital, Zhejiang University School of Medicine during October 2013 and April 2017 were included in the study.Among 115 patients, 30 received tirofiban treatment.Hemorrhagic transformation and neurological outcomes were assessed using the ECASSⅡcriteria and modified Rankin scale(mRS),respectively.Unfavorable outcome was defined as mRS >2.Binary logistic regression model was used to analyze the independent predictors of hemorrhagic transformation and neurological outcome.Results:Binary logistic regression analysis showed that tirofiban treatment did not increase the risk of hemorrhagic transformation(OR =0.437, 95% CI: 0.168 -1.132, P >0.05);baseline NIHSS(OR =1.136, 95% CI:1.014 -1.273, P <0.05), recanalization (OR=0.060,95%CI:0.010-0.365,P<0.01), hypertension(OR=4.233,95%CI:1.320-13.570, P<0.05)and onset to treatment time(OR=1.006,95% CI:1.001-1.011, P <0.05)were independently associated with unfavorable outcome, while such association was not observed in tirofiban treatment(OR=1.923,95% CI:0.536-6.568, P>0.05).Conclusion: Tirofiban appears to be safe for patients with acute cerebral infarct receiving endovascular therapy. |
| Author | 冯学问;陈智才;钟根龙;楼敏 |
| AuthorAffiliation | 浙江大学医学院附属第二医院神经内科,浙江杭州310009;温岭市第一人民医院神经内科,浙江温岭317500 |
| AuthorAffiliation_xml | – name: 浙江大学医学院附属第二医院神经内科,浙江杭州310009;温岭市第一人民医院神经内科,浙江温岭317500%浙江大学医学院附属第二医院神经内科,浙江杭州,310009 |
| Author_FL | LOU Min ZHONG Genlong FENG Xuewen CHEN Zhicai |
| Author_FL_xml | – sequence: 1 fullname: FENG Xuewen – sequence: 2 fullname: CHEN Zhicai – sequence: 3 fullname: ZHONG Genlong – sequence: 4 fullname: LOU Min |
| Author_xml | – sequence: 1 fullname: 冯学问;陈智才;钟根龙;楼敏 |
| BookMark | eNo9kM1Kw0AUhWdRwVr7ErqUxJnMJJNZSvEPCm66chPyM6kpmmqD2LoKYosK2iLFgmKhithNu3AlVfFlTKZ9C1Mqchf3cvjuOXAWQMov-xyAZQRlTHV1tSR7QeDLCEJdYgpTZAUiKkNdhiwF0v_yPMgGgWdBFWGaDEyD3Th8icNX8Tka98LkiK5vf94H8dnzOKwnihj2okY9fvsQd52odRON2qLdjx--xVdn8tgVzYG4P4-Gl1G9P_1tXk2ezqfYRSPuthbBnGvuBzz7tzOgsLFeyG1J-Z3N7dxaXrI1zCTCmWNTotiYIMw1V3Up0bmqWxRpnLiKqTpcVRzXsUydEK5BzeHIdC3bZgxSpOAMWJnZnpi-a_pFo1Q-rvhJoHFacqpVy6hVrWkbkEDIEnppRtt7Zb945CX8YcU7MCs1Q6OYMaJihH8BQVKE6A |
| ClassificationCodes | R743.3 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3785/j.issn.1008-9292.2017.08.09 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy |
| DocumentTitle_FL | Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy |
| EndPage | 404 |
| ExternalDocumentID | zjdxxb_yxb201704009 673994531 |
| GrantInformation_xml | – fundername: 国家自然科学基金 funderid: (81471170,81622017) |
| GroupedDBID | 2RA 92L ALMA_UNASSIGNED_HOLDINGS CQIGP RPM W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| ID | FETCH-LOGICAL-c639-4e9dc742c3413e6f5f748e58b716e4f2a5de52dfdba844e606de1afbcc9907123 |
| ISSN | 1008-9292 |
| IngestDate | Thu May 29 04:07:21 EDT 2025 Wed Feb 14 10:03:45 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Prognosis Tyrosine/analogs&derivatives 酪氨酸/类似物和衍生物 Hemorrhage/prevention&control Platelet membrane glycoproteins/antagonists&inhibitors 动脉闭塞性疾病/药物疗法 血栓溶解疗法 血小板膜糖蛋白类/拮抗剂和抑制剂 脑缺血/治疗 Brain ischemia/therapy 预后 出血/预防和控制 Arterial occlusive diseases/drug therapy Thrombolytic therapy |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c639-4e9dc742c3413e6f5f748e58b716e4f2a5de52dfdba844e606de1afbcc9907123 |
| Notes | Objective： To investigate the effect of tirofiban on hemorrhagic transformation and neurological outcome in patients with acute cerebral infarct treated with endovascular therapy. Methods： One hundred and fifteen patients with acute cerebral infarct who received endovascular stent mechanical thrombectomy in the Second Affiliated Hospital, Zhejiang University School of Medicine during October 2013 and April 2017 were included in the study. Among 115 patients, 30 received tirofiban treatment. Hemorrhagic transformation and neurological outcomes were assessed using the ECASS I1 criteria and modified Rankin scale （mRS）, respectively. Unfavorable outcome was defined as mRS 〉 2. Binary logistic regression model was used to analyze the independent predictors of hemorrhagic transformation and neurological outcome. Results： Binary logistic regression analysis showed that tirofiban treatment did not increase the risk of hemorrhagic transformation （ OR = 0. 437, 95% CI： O. 168 - 1. 132, P 〉 0.05 ） ; baseline NIHSS （ OR |
| PageCount | 8 |
| ParticipantIDs | wanfang_journals_zjdxxb_yxb201704009 chongqing_primary_673994531 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 浙江大学学报（医学版） |
| PublicationTitleAlternate | Journal of Zhejiang University（Medical Sciences） |
| PublicationTitle_FL | Journal of Zhejiang University(Medical Sciences) |
| PublicationYear | 2017 |
| Publisher | 温岭市第一人民医院神经内科,浙江温岭317500%浙江大学医学院附属第二医院神经内科,浙江杭州,310009 浙江大学医学院附属第二医院神经内科,浙江杭州310009 |
| Publisher_xml | – name: 浙江大学医学院附属第二医院神经内科,浙江杭州310009 – name: 温岭市第一人民医院神经内科,浙江温岭317500%浙江大学医学院附属第二医院神经内科,浙江杭州,310009 |
| SSID | ssib051373730 ssib002263662 ssib009993744 ssib006576290 ssib006704889 ssib012436470 ssj0002507821 ssib006562844 ssib002039758 ssib008143987 ssib008679799 ssib001051301 ssib001104240 ssib056826211 ssib058720545 |
| Score | 2.1104834 |
| Snippet | 目的：探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法：回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取... R743.3; 目的:探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析.方法:回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 397 |
| SubjectTerms | 出血／预防和控制 动脉闭塞性疾病／药物疗法 类似物和衍生物 脑缺血／治疗 血小板膜糖蛋白类／拮抗剂和抑制剂 血栓溶解疗法 酪氨霞龟 预后 |
| Title | 急性缺血性卒中患者血管内治疗后应用替罗非班的安全性及预后分析 |
| URI | http://lib.cqvip.com/qk/91095A/201704/673994531.html https://d.wanfangdata.com.cn/periodical/zjdxxb-yxb201704009 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (selected full-text only) issn: 1008-9292 databaseCode: M~E dateStart: 19990101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: true ssIdentifier: ssib056826211 providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central issn: 1008-9292 databaseCode: RPM dateStart: 20150101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ omitProxy: true ssIdentifier: ssj0002507821 providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxQxFA9tBfEiioq1Wgo2x62zM5lMcpzpzlAEPVUoXtadr1YPWz9aqD3IIm1RQVukWFAsVBF7aQ-epCr-M-5O-1_4XmZ2NpZSVBaGR_Ly3puX3X2_JC8JIaMMIHEsjBSQmxVXIB7blVAysxKFzEhtIxEyUgmyN_nELXZ9yp7q67-jZS3Nz4Vj0eKR-0r-p1ehDPoVd8n-Q8-WQqEAaOhfeEIPw_Ov-pj6HDMVXLtLONR3qDdOPZf6grpVLOxV2VTUqDSpz6gHtTVVZVLXQmbgEbbWyqGujzS24qqKU8-knodVklOpBEpo5SMBGiVTVYy6ApmlR71A2VNTzJJKIHwsEYHSDswuFQybgy4hlS67aN6zOaDCxeauWTCXSoVA21CXT_PrQLs4W1kLnFIRVSoDpYUVMkG7yzWCowp0Y4DeA6tQ-Lh62ZLHQQtFmflbOMYNNBaJLwqvYnmKRnZlnVQdwpWAWrfWVEaBBIN6Eks8HzmxlqMtYAi2RQfoUzP5HtQijmBWCSDPPwJNMdd6V59FUVHDylOUCwDC8vuYD8c2yxG2im2oYKxUgNmJjjqFVvZCeployR0AoMzGgwZOmDhjdWg-C9A1gBj9AEBcCtcAoQG2aevmANYtrh0wCaMBU2gAkcPw1dTWXbmDEaIHmAXAc6kNCPC4R31dWSJc7skD8In3G5TywFgHPkY5iwoAHiCumlXpOuQkuVp469oxvsKjVGZmm9MPACCq_XrNtNGc1qDl5BlyuhgTjrj5D_ws6VucOUdud1qfOq3P2fe9_a0WEO2Xr3993ek8_bjfWoaSbHervbLc-fIte7PRXnvV3lvP1rc7735mPzYO3m9mqzvZ26X27vP28ja2XX1x8GEJ2Z6tdDbXzpPJwJ8cn6gUF6FUIo6JGomMI4eZESLOhKd26jCR2CJ0qjxhqdmw48Q24zQOG9AXCTd4nFQbaRhFADUdgKYXyEBztplcJCPSCmMRJimMGgQLRSwxszgJecxEzJi0BslQ6Zb6_fy8m3r5JRoko4Wj6sW_4KP64r14YSGsP14I0bkICeSlY4UMkVPImU9jXiYDcw_nkysA7OfCYdJ_44k_rL6hvwFDN8G3 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%80%A5%E6%80%A7%E7%BC%BA%E8%A1%80%E6%80%A7%E5%8D%92%E4%B8%AD%E6%82%A3%E8%80%85%E8%A1%80%E7%AE%A1%E5%86%85%E6%B2%BB%E7%96%97%E5%90%8E%E5%BA%94%E7%94%A8%E6%9B%BF%E7%BD%97%E9%9D%9E%E7%8F%AD%E7%9A%84%E5%AE%89%E5%85%A8%E6%80%A7%E5%8F%8A%E9%A2%84%E5%90%8E%E5%88%86%E6%9E%90&rft.jtitle=%E6%B5%99%E6%B1%9F%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5%EF%BC%9A%E5%8C%BB%E5%AD%A6%E7%89%88&rft.au=%E5%86%AF%E5%AD%A6%E9%97%AE%3B%E9%99%88%E6%99%BA%E6%89%8D%3B%E9%92%9F%E6%A0%B9%E9%BE%99%3B%E6%A5%BC%E6%95%8F&rft.date=2017&rft.issn=1008-9292&rft.volume=46&rft.issue=4&rft.spage=397&rft.epage=404&rft_id=info:doi/10.3785%2Fj.issn.1008-9292.2017.08.09&rft.externalDocID=673994531 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91095A%2F91095A.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzjdxxb-yxb%2Fzjdxxb-yxb.jpg |